[go: up one dir, main page]

NO941422L - - Google Patents

Info

Publication number
NO941422L
NO941422L NO941422A NO941422A NO941422L NO 941422 L NO941422 L NO 941422L NO 941422 A NO941422 A NO 941422A NO 941422 A NO941422 A NO 941422A NO 941422 L NO941422 L NO 941422L
Authority
NO
Norway
Prior art keywords
immunogen
disclosed
isolated antibody
antibody immunoreactive
immunoreactive
Prior art date
Application number
NO941422A
Other languages
English (en)
Norwegian (no)
Other versions
NO317625B1 (no
NO941422D0 (no
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO941422(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO941422D0 publication Critical patent/NO941422D0/no
Publication of NO941422L publication Critical patent/NO941422L/no
Publication of NO317625B1 publication Critical patent/NO317625B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19941422A 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat. NO317625B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05
PCT/US1992/008990 WO1993008207A1 (en) 1991-10-25 1992-10-23 Novel cytokine

Publications (3)

Publication Number Publication Date
NO941422D0 NO941422D0 (no) 1994-04-19
NO941422L true NO941422L (fi) 1994-06-27
NO317625B1 NO317625B1 (no) 2004-11-29

Family

ID=27120174

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19941422A NO317625B1 (no) 1991-10-25 1994-04-19 Ligand til CD40 reseptoren, DNA, Vektor, Vertcelle, Fremgangsmate for fremstilling, Protein og Farmasoytisk preparat.
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO19980030A NO320073B1 (no) 1991-10-25 1998-01-05 Antistoffer som binder CD40-L

Country Status (13)

Country Link
EP (2) EP0897983B1 (fi)
JP (2) JP3308534B2 (fi)
KR (1) KR100283541B1 (fi)
AT (2) ATE239790T1 (fi)
AU (1) AU661360B2 (fi)
CA (2) CA2121798C (fi)
DE (2) DE69233402T3 (fi)
DK (3) DK0667901T4 (fi)
ES (2) ES2198025T3 (fi)
FI (2) FI116850B (fi)
HK (1) HK1019343A1 (fi)
NO (2) NO317625B1 (fi)
WO (1) WO1993008207A1 (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5560908A (en) * 1993-01-22 1996-10-01 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
PT679191E (pt) * 1993-01-22 2004-04-30 Immunex Corp Deteccao e tratamento de mutacoes num gene de ligando de cd40
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
EP0742721B1 (en) * 1993-09-02 1999-05-06 Trustees of Dartmouth College Methods of prolonged suppression of humoral immunity
KR100398819B1 (ko) * 1993-09-02 2004-02-05 트러스티스 오브 다트마우스 칼리지 gp39길항제를포함하는약제조성물
ES2120067T3 (es) 1993-09-02 1998-10-16 Dartmouth College Metodos para inducir tolerancia de celulas t antigeno especifica.
WO1995014487A1 (en) * 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
PT751781E (pt) * 1993-12-23 2004-09-30 Nat Inst Of Health As Repr By Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
JP3881691B2 (ja) 1994-04-28 2007-02-14 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｂ細胞の増殖方法及び分化方法並びにその使用
PT812206E (pt) * 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
DE69631331T2 (de) * 1995-06-07 2004-11-18 Immunex Corp., Seattle Cd40l mutein
CA2224812A1 (en) * 1995-06-22 1997-01-09 Biogen, Inc. Crystals of fragments of cd40 ligand and their use
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US5971158A (en) * 1996-06-14 1999-10-26 University Of Washington Absorption-enhanced differential extraction device
JP2002514047A (ja) * 1996-07-10 2002-05-14 イミュネックス・コーポレーション 樹状細胞を活性化する方法
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DK2009025T3 (da) 1998-05-14 2011-11-14 Immunex Corp Fremgangsmåde til hæmning af osteoklast-aktivitet
JP3820105B2 (ja) * 1998-10-23 2006-09-13 キリン−アムジエン・インコーポレーテツド Ｍｐ１受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1173589A1 (en) * 1999-04-16 2002-01-23 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
WO2001087330A2 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CA2424749A1 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
AU2002221780A1 (en) * 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
EP1434871B1 (en) 2001-09-20 2017-01-18 Immunex Corporation Selection of cells expressing heteromeric polypeptides
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
MXPA05008523A (es) 2003-02-14 2005-10-20 Biogen Idec Inc Un casete de expresion y vector para la expresion transitoria o estable de moleculas exogenas.
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US7928205B2 (en) 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
CN103555651A (zh) 2006-09-13 2014-02-05 Abbvie公司 细胞培养改良
ES2520026T3 (es) 2006-09-18 2014-11-11 The Board Of Trustees Of The University Of Arkansas Composiciones y métodos para potenciar respuestas inmunitarias
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
CN102037135A (zh) 2007-10-30 2011-04-27 阿肯色大学评议会 增强对有鞭毛的细菌的免疫反应的组合物和方法
AU2008318357B2 (en) 2007-11-01 2015-01-22 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
EP2784089A1 (en) 2008-01-15 2014-10-01 AbbVie Inc. Improved mammalian expression vectors and uses thereof
ES2642629T3 (es) 2009-11-17 2017-11-17 E. R. Squibb & Sons, L.L.C. Métodos para la producción mejorada de proteínas
AU2011207331C1 (en) 2010-01-21 2016-05-12 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
SG10202109925TA (en) 2013-02-14 2021-10-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CN114605549A (zh) 2015-08-05 2022-06-10 詹森生物科技公司 抗cd154抗体及其使用方法
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
ES2914118T3 (es) 2016-05-11 2022-06-07 Amgen Inc Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
JP7260477B2 (ja) 2017-02-27 2023-04-18 シャタック ラボ，インコーポレイテッド Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP7121029B2 (ja) * 2017-02-27 2022-08-17 シャタック ラボ，インコーポレイテッド Ｃｓｆ１ｒベースのキメラタンパク質

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
NO980030D0 (no) 1998-01-05
DK0667901T4 (da) 2008-11-10
CA2121798C (en) 2007-07-24
FI116828B (fi) 2006-03-15
EP0897983B1 (en) 2003-05-07
DK0667901T3 (da) 2004-12-27
NO980030L (no) 1998-01-05
EP0667901B1 (en) 2004-08-18
DE69233051T2 (de) 2004-03-11
CA2121798A1 (en) 1993-04-29
HK1019343A1 (en) 2000-02-03
DK0897983T3 (da) 2003-08-11
EP0667901A1 (en) 1995-08-23
EP0897983A2 (en) 1999-02-24
NO317625B1 (no) 2004-11-29
CA2312667C (en) 2002-11-19
ES2198025T3 (es) 2004-01-16
EP0897983A3 (en) 1999-03-17
KR100283541B1 (ko) 2001-03-02
CA2312667A1 (en) 1993-04-29
ATE274055T1 (de) 2004-09-15
JP3308534B2 (ja) 2002-07-29
EP0667901A4 (en) 1995-06-22
FI981765L (fi) 1998-08-17
NO320073B1 (no) 2005-10-17
JPH10150994A (ja) 1998-06-09
FI116850B (fi) 2006-03-15
FI941837A0 (fi) 1994-04-20
JP2877788B2 (ja) 1999-03-31
FI941837L (fi) 1994-05-30
DE69233051D1 (de) 2003-06-12
AU661360B2 (en) 1995-07-20
DE69233402D1 (de) 2004-09-23
ATE239790T1 (de) 2003-05-15
FI981765A0 (fi) 1998-08-17
DK0822199T3 (da) 2004-12-27
JPH07504083A (ja) 1995-05-11
EP0667901B2 (en) 2008-10-15
DE69233402T3 (de) 2009-06-25
ES2227513T5 (es) 2009-04-01
AU3122693A (en) 1993-05-21
DE69233402T2 (de) 2005-09-15
ES2227513T3 (es) 2005-04-01
WO1993008207A1 (en) 1993-04-29
NO941422D0 (no) 1994-04-19

Similar Documents

Publication Publication Date Title
NO941422L (fi)
GB2216256B (en) Optical encoder.
GB2222695B (en) Optical seeker with rosette scanning
AU5567990A (en) Rectified intraocular lens
EP0340779A3 (en) Optical quantum interference device
YU234889A (en) Optical transistor
DE68916079D1 (de) Intraokulare Linse.
EP0469853A3 (en) Light guide
AU586607B2 (en) Device for scanning a radiation-reflecting information surface with optical radiation
EP0507213A3 (en) Light transmitter
GB2226246B (en) Intraocular lens
TW198026B (fi)
ES2054986T3 (es) N-arilacion de isatinas.
DE68917796D1 (de) Intraokulare Linse.
DE3765979D1 (de) Intraokulare linse mit verminderter blendwirkung.
BR8902568A (pt) Freio mecanico com ajuste automatico
DE69104049D1 (de) Mechanisch betätigte bremse mit automatischer justierung.
IT223115Z2 (it) Bruciatore a "rampete" con combustione cosiddetta iperstechiometrica
AU3482589A (en) Black light photocopier
AU6861691A (en) Valve guide relining sleeve
GB9102177D0 (en) Photo diode
AU1205192A (en) Novel thyroid antigen
CA65789S (en) Handle for adjusting the position of a light
CS909588A1 (en) Connection for control valve's extreme positions automatic scanning
NO894118D0 (no) Fremgangsmaate for regulering av en tresliper.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees